Tumor lysis syndrome cost-effectiveness of therapy: Difference between revisions
No edit summary |
Mahshid |
||
| Line 16: | Line 16: | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Revision as of 17:25, 27 November 2017
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome cost-effectiveness of therapy |
|
Tumor lysis syndrome cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Tumor lysis syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.[1]
Cost-Effectiveness of Therapy
In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.[1]
References
- ↑ 1.0 1.1 Patel S, Le A, Gascon S (2012). "Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome". Am J Health Syst Pharm. 69 (12): 1015–6. doi:10.2146/ajhp110656. PMID 22644973.